[1] |
XU L H, CHEN L Y, GU G Y, et al. Natural products from traditional Chinese medicine for the prevention and treatment of heart failure: progress and perspectives[J]. Rev Cardiovasc Med, 2022, 23(2):60. doi: 10.31083/j.rcm2302060 |
[2] |
WANG A Z, ZHAO W, YAN K T, et al. Mechanisms and efficacy of traditional Chinese medicine in heart failure[J]. Front Pharmacol, 2022, 13:810587. doi: 10.3389/fphar.2022.810587 |
[3] |
FU S F, ZHANG J H, GAO X M, et al. Clinical practice of traditional Chinese medicines for chronic heart failure[J]. Heart Asia, 2010, 2(1):24-27. doi: 10.1136/ha.2009.001123 |
[4] |
ZANG Y B, WAN J J, ZHANG Z, et al. An updated role of astragaloside IV in heart failure[J]. Biomed Pharmacother, 2020, 126:110012. doi: 10.1016/j.biopha.2020.110012 |
[5] |
WANG Y, WANG Q Y, LI C, et al. A review of Chinese herbal medicine for the treatment of chronic heart failure[J]. Curr Pharm Des, 2017, 23(34):5115-5124. |
[6] |
MA X, ZHANG K, LI H X, et al. Extracts from Astragalus membranaceus limit myocardial cell death and improve cardiac function in a rat model of myocardial ischemia[J]. J Ethnopharmacol, 2013, 149(3):720-728. doi: 10.1016/j.jep.2013.07.036 |
[7] |
ZHOU R J, CHEN H J, CHEN J P, et al. Extract from Astragalus membranaceus inhibit breast cancer cells proliferation via PI3K/AKT/mTOR signaling pathway[J]. BMC Complementary Altern Med, 2018, 18(1):83. doi: 10.1186/s12906-017-2057-9 |
[8] |
FRANK A, BONNEY M, BONNEY S, et al. Myocardial ischemia reperfusion injury: from basic science to clinical bedside[J]. Semin Cardiothorac Vasc Anesth, 2012, 16(3):123-132. doi: 10.1177/1089253211436350 |
[9] |
YIN B, HOU X W, LU M L. Astragaloside IV attenuates myocardial ischemia/reperfusion injury in rats via inhibition of calcium-sensing receptor-mediated apoptotic signaling pathways[J]. Acta Pharmacol Sin, 2019, 40(5):599-607. doi: 10.1038/s41401-018-0082-y |
[10] |
FISCHER P, HILFIKER-KLEINER D. Survival pathways in hypertrophy and heart failure: the gp130-STAT3 axis[J]. Basic Res Cardiol, 2007, 102(4):279-297. doi: 10.1007/s00395-007-0658-z |
[11] |
DENISE H K, PRAPHULLA S, GUNNAR K, et al. Continuous glycoprotein-130-mediated signal transducer and activator of transcription-3 activation promotes inflammation, left ventricular rupture, and adverse outcome in subacute myocardial infarction[J]. Circulation, 2010, 122(2):145-155. doi: 10.1161/CIRCULATIONAHA.109.933127 |
[12] |
ZHAO P, WANG Y, ZENG S, et al. Protective effect of astragaloside IV on lipopolysaccharide-induced cardiac dysfunction via downregulation of inflammatory signaling in mice[J]. Immunopharmacol Immunotoxicol, 2015, 37(5):428-433. doi: 10.3109/08923973.2015.1080266 |
[13] |
ZHOU R N, SONG Y L, RUAN J Q, et al. Pharmacokinetic evidence on the contribution of intestinal bacterial conversion to beneficial effects of astragaloside IV, a marker compound of astragali Radix, in traditional oral use of the herb[J]. Drug Metab Pharmacokinet, 2012, 27(6):586-597. doi: 10.2133/dmpk.DMPK-11-RG-160 |
[14] |
SUN C H, JIANG M M, ZHANG L, et al. Cycloastragenol mediates activation and proliferation suppression in concanavalin A-induced mouse lymphocyte pan-activation model[J]. Immunopharmacol Immunotoxicol, 2017, 39(3):131-139. doi: 10.1080/08923973.2017.1300170 |
[15] |
TAN S F, WANG G F, GUO Y P, et al. Preventive effects of a natural anti-inflammatory agent, astragaloside IV, on ischemic acute kidney injury in rats[J]. Evid Based Complement Alternat Med, 2013, 2013:284025. |
[16] |
GUO H T, CALLAWAY J B, TING J P-Y. Inflammasomes: mechanism of action, role in disease, and therapeutics[J]. Nat Med, 2015, 21(7):677-687. doi: 10.1038/nm.3893 |
[17] |
WANG J, WU M L, CAO S P, et al. Cycloastragenol ameliorates experimental heart damage in rats by promoting myocardial autophagy via inhibition of AKT1-RPS6KB1 signaling[J]. Biomed Pharmacother, 2018, 107:1074-1081. doi: 10.1016/j.biopha.2018.08.016 |
[18] |
LI M, HAN B, ZHAO H, et al. Biological active ingredients of astragali radix and its mechanisms in treating cardiovascular and cerebrovascular diseases[J]. Phytomedicine, 2022, 98:153918. doi: 10.1016/j.phymed.2021.153918 |
[19] |
ZHANG L, FAN C D, JIAO H C, et al. Calycosin alleviates doxorubicin-induced cardiotoxicity and pyroptosis by inhibiting NLRP3 inflammasome activation[J]. Oxid Med Cell Longev, 2022, 2022:1733834. |
[20] |
CHEN G H, XU H L, XU T, et al. Calycosin reduces myocardial fibrosis and improves cardiac function in post-myocardial infarction mice by suppressing TGFBR1 signaling pathways[J]. Phytomedicine, 2022, 104:154277. doi: 10.1016/j.phymed.2022.154277 |
[21] |
RÍOS J L, ANDÚJAR I, RECIO M C, et al. Lanostanoids from fungi: a group of potential anticancer compounds[J]. J Nat Prod, 2012, 75(11):2016-2044. doi: 10.1021/np300412h |
[22] |
ESTEBAN C I. Interés medicinal de Poria Cocos (= Wolfiporia extensa)[J]. Rev Iberoam De Micología, 2009, 26(2):103-107. |
[23] |
RÍOS J L. Chemical constituents and pharmacological properties of Poria cocos[J]. Planta Med, 2011, 77(7):681-691. doi: 10.1055/s-0030-1270823 |
[24] |
VAN DER POL A, VAN GILST W H, VOORS A A, et al. Treating oxidative stress in heart failure: past, present and future[J]. Eur J Heart Fail, 2019, 21(4):425-435. doi: 10.1002/ejhf.1320 |
[25] |
LI X, CHEN S, LI J E, et al. Chemical composition and antioxidant activities of polysaccharides from Yingshan cloud mist tea[J]. Oxidative Med Cell Longev, 2019, 2019:1915967. |
[26] |
LIU X F, WANG X Q, XU X F, et al. Purification, antitumor and anti-inflammation activities of an alkali-soluble and carboxymethyl polysaccharide CMP33 from Poria cocos[J]. Int J Biol Macromol, 2019, 127:39-47. doi: 10.1016/j.ijbiomac.2019.01.029 |
[27] |
WEI C Y, WANG H Z, SUN X, et al. Pharmacological profiles and therapeutic applications of pachymic acid (Review)[J]. Exp Ther Med, 2022, 24(3):547. doi: 10.3892/etm.2022.11484 |
[28] |
LI F F, YUAN Y, LIU Y, et al. Pachymic acid protects H9c2 cardiomyocytes from lipopolysaccharide-induced inflammation and apoptosis by inhibiting the extracellular signal-regulated kinase 1/2 and p38 pathways[J]. Mol Med Rep, 2015, 12(2):2807-2813. doi: 10.3892/mmr.2015.3712 |
[29] |
HUANG Y C, CHANG W L, HUANG S F, et al. Pachymic acid stimulates glucose uptake through enhanced GLUT4 expression and translocation[J]. Eur J Pharmacol, 2010, 648(1-3):39-49. doi: 10.1016/j.ejphar.2010.08.021 |
[30] |
LUO C M, YI F L, XIA Y L, et al. Comprehensive quality evaluation of the lateral root of Aconitum carmichaelii Debx. (Fuzi): simultaneous determination of nine alkaloids and chemical fingerprinting coupled with chemometric analysis[J]. J Sep Sci, 2019, 42(5):980-990. |
[31] |
LIN S Q, LIU K X, WU W K, et al. Study on pretreatment of FPS-1 in rats with hepatic ischemia-reperfusion injury[J]. Am J Chin Med, 2009, 37(2):323-337. doi: 10.1142/S0192415X09006874 |
[32] |
LU Y J, ZHOU J, XU C Q, et al. JAK/STAT and PI3K/AKT pathways form a mutual transactivation loop and afford resistance to oxidative stress-induced apoptosis in cardiomyocytes[J]. Cell Physiol Biochem, 2008, 21(4):305-314. doi: 10.1159/000129389 |
[33] |
LU X H, ZHANG L, LI P Y, et al. The protective effects of compatibility of Aconiti Lateralis Radix Praeparata and Zingiberis Rhizoma on rats with heart failure by enhancing mitochondrial biogenesis via Sirt1/PGC-1α pathway[J]. Biomed Pharmacother, 2017, 92:651-660. doi: 10.1016/j.biopha.2017.05.117 |
[34] |
WU H, LIU X, GAO Z Y, et al. Anti-myocardial infarction effects of Radix aconiti lateralis preparata extracts and their influence on small molecules in the heart using matrix-assisted laser desorption/ionization–mass spectrometry imaging[J]. Int J Mol Sci, 2019, 20(19):4837. doi: 10.3390/ijms20194837 |
[35] |
CHAN T F, CHAN J C, TOMLINSON B, et al. Chinese herbal medicines revisited: a Hong Kong perspective[J]. Lancet, 1993, 342(8886-8887):1532-1534. doi: 10.1016/S0140-6736(05)80091-1 |
[36] |
LIU M, CAO Y, LV D Y, et al. Effect of processing on the alkaloids in Aconitum tubers by HPLC-TOF/MS[J]. J Pharm Anal, 2017, 7(3):170-175. doi: 10.1016/j.jpha.2017.01.001 |
[37] |
HONERJÄGER P, MEISSNER A. The positive inotropic effect of aconitine[J]. Naunyn-Schmiedeberg's Arch Pharmacol, 1983, 322(1):49-58. doi: 10.1007/BF00649352 |
[38] |
WU M P, ZHANG Y S, ZHOU Q M, et al. Higenamine protects ischemia/reperfusion induced cardiac injury and myocyte apoptosis through activation of β2-AR/PI3K/AKT signaling pathway[J]. Pharmacol Res, 2016, 104:115-123. doi: 10.1016/j.phrs.2015.12.032 |
[39] |
LOPASCHUK G D, KARWI Q G, TIAN R, et al. Cardiac energy metabolism in heart failure[J]. Circ Res, 2021, 128(10):1487-1513. doi: 10.1161/CIRCRESAHA.121.318241 |
[40] |
WANG D, LU C Y, TENG L S, et al. Therapeutic effects of Chinese herbal medicine against neuroendocrinological diseases especially related to hypothalamus-pituitary-adrenal and hypothalamus-pituitary-gonadal axis[J]. Pak J Pharm Sci, 2014, 27(3-Suppl):741-754. |
[41] |
TSAI M Y, YANG R C, WU H T, et al. Anti-angiogenic effect of Tanshinone IIA involves inhibition of matrix invasion and modification of MMP-2/TIMP-2 secretion in vascular endothelial cells[J]. Cancer Lett, 2011, 310(2):198-206. doi: 10.1016/j.canlet.2011.06.031 |
[42] |
LI X, DU J R, YU Y, et al. Tanshinone IIA inhibits smooth muscle proliferation and intimal hyperplasia in the rat carotid balloon-injured model through inhibition of MAPK signaling pathway[J]. J Ethnopharmacol, 2010, 129(2):273-279. doi: 10.1016/j.jep.2010.03.021 |
[43] |
REN Z H, TONG Y H, XU W, et al. Tanshinone II A attenuates inflammatory responses of rats with myocardial infarction by reducing MCP-1 expression[J]. Phytomedicine, 2010, 17(3-4):212-218. doi: 10.1016/j.phymed.2009.08.010 |
[44] |
TAKAHASHI M. NLRP3 inflammasome as a novel player in myocardial infarction[J]. Int Heart J, 2014, 55(2):101-105. doi: 10.1536/ihj.13-388 |
[45] |
MA Y Z, LI H, YUE Z B, et al. Cryptotanshinone attenuates cardiac fibrosis via downregulation of COX-2, NOX-2, and NOX-4[J]. J Cardiovasc Pharmacol, 2014, 64(1):28-37. doi: 10.1097/FJC.0000000000000086 |
[46] |
JIN Y C, KIM C W, KIM Y M, et al. Cryptotanshinone, a lipophilic compound of Salvia miltiorrriza root, inhibits TNF-alpha-induced expression of adhesion molecules in HUVEC and attenuates rat myocardial ischemia/reperfusion injury in vivo[J]. Eur J Pharmacol, 2009, 614(1-3):91-97. doi: 10.1016/j.ejphar.2009.04.038 |
[47] |
ZHANG Y S, CHEN L, LI F, et al. Cryptotanshinone protects against adriamycin-induced mitochondrial dysfunction in cardiomyocytes[J]. Pharm Biol, 2016, 54(2):237-242. doi: 10.3109/13880209.2015.1029052 |
[48] |
MA S T,YANG D C,WANG K Y,et.al. Cryptotanshinone attenuates isoprenaline-induced cardiac fibrosis in mice associated with upregulation and activation of matrix metalloproteinase-2[J]. Mol Med Report, 2012, 6(1):145-150. |
[49] |
SONG Q T, CHU X, ZHANG X, et al. Mechanisms underlying the cardioprotective effect of Salvianic acid A against isoproterenol-induced myocardial ischemia injury in rats: possible involvement of L-type calcium channels and myocardial contractility[J]. J Ethnopharmacol, 2016, 189:157-164. doi: 10.1016/j.jep.2016.05.038 |
[50] |
ANDRASSY M, VPLZ H C, IGWE J C, et al. High-mobility group box-1 in ischemia-reperfusion injury of the heart[J]. Circulation, 2008, 117(25): 3216-3226. |
[51] |
XIANG J, ZHANG C L, DI T T, et al. Salvianolic acid B alleviates diabetic endothelial and mitochondrial dysfunction by down-regulating apoptosis and mitophagy of endothelial cells[J]. Bioengineered, 2022,13(2): 3486-3502. |
[52] |
ZHOU Z, LIU Y, MIAO A D, et al. Salvianolic acid B attenuates plasminogen activator inhibitor type 1 production in TNF-alpha treated human umbilical vein endothelial cells[J]. J Cell Biochem, 2005, 96(1):109-116. doi: 10.1002/jcb.20567 |
[53] |
VAN DER POL A, VAN GILST W H, VOORS A A, et al. Treating oxidative stress in heart failure: past, present 1and future[J]. Eur J Heart Fail, 2019, 21(4): 425-435. |
[54] |
LI C Y, YANG P, JIANG Y L, et al. Ginsenoside Rb1 attenuates cardiomyocyte apoptosis induced by myocardial ischemia reperfusion injury through mTOR signal pathway[J]. Biomed Pharmacother, 2020, 125:109913. doi: 10.1016/j.biopha.2020.109913 |
[55] |
WU Y, XIA Z Y, MENG Q T, et al. Shen-Fu injection preconditioning inhibits myocardial ischemia-reperfusion injury in diabetic rats: activation of eNOS via the PI3K/Akt pathway[J]. J Biomed Biotechnol, 2011, 2011:384627. |
[56] |
HUANG L Z, ZHAO H F, HUANG B K, et al. Acanthopanax senticosus: review of botany, chemistry and pharmacology[J]. Pharmazie, 2011, 66(2):83-97. |
[57] |
NIU J, PI Z F, YUE H, et al. Effect of ginseng polysaccharide on the urinary excretion of type 2 diabetic rats studied by liquid chromatography–mass spectrometry[J]. Analyt Teehnot. Biomed Life Sci, 2012, 907:7-12. doi: 10.1016/j.jchromb.2012.08.012 |
[58] |
LI C, CAI J P, GENG J S, et al. Purification, characterization and anticancer activity of a polysaccharide from Panax ginseng[J]. Int J Biol Macromol, 2012, 51(5):968-973. doi: 10.1016/j.ijbiomac.2012.06.031 |
[59] |
KIM M H, BYON Y Y, KO E J, et al. Immunomodulatory activity of ginsan, a polysaccharide of Panax ginseng, on dendritic cells[J]. Korean J Physiol Pharmacol, 2009, 13(3):169-173. doi: 10.4196/kjpp.2009.13.3.169 |